Suppr超能文献

为脊髓性肌萎缩症新生儿筛查检测支付费用的意愿。

Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy.

作者信息

Lin Pei-Jung, Yeh Wei-Shi, Neumann Peter J

机构信息

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

Health Economics and Outcomes Research, Global Market Access, Biogen, Cambridge, Massachusetts.

出版信息

Pediatr Neurol. 2017 Jan;66:69-75. doi: 10.1016/j.pediatrneurol.2016.09.008. Epub 2016 Sep 15.

Abstract

OBJECTIVES

The current US mandatory newborn screening panel does not include spinal muscular atrophy, the most common fatal genetic disease among children. We assessed population preferences for newborn screening for spinal muscular atrophy, and how test preferences varied depending on immediate treatment implications.

METHODS

We conducted an online willingness-to-pay survey of US adults (n = 982). Respondents were asked to imagine being parents of a newborn. Each respondent was presented with two hypothetical scenarios following the spinal muscular atrophy screening test: current standard of care (no treatment available) and one of three randomly assigned scenarios (new treatment available to improve functioning, survival, or both). We used a bidding game to elicit willingness to pay for the spinal muscular atrophy test, and performed a two-part model to estimate median and mean willingness-to-pay values.

RESULTS

Most respondents (79% to 87%) would prefer screening their newborns for spinal muscular atrophy. People expressed a willingness to pay for spinal muscular atrophy screening even without an available therapy (median: $142; mean: $253). Willingness to pay increased with treatment availability (median: $161 to $182; mean: $270 to $297) and respondent income. Most respondents considered test accuracy, treatment availability, and treatment effectiveness very important or important factors in deciding willingness to pay.

CONCLUSIONS

Most people would prefer and would be willing to pay for testing their newborn for spinal muscular atrophy, even in the absence of direct treatment. People perceive the spinal muscular atrophy test more valuable if treatment were available to improve the newborn's functioning and survival. Despite preferences for the test information, adding spinal muscular atrophy to newborn screening programs remains controversial. Future studies are needed to determine how early detection may impact long-term patient outcomes.

摘要

目的

美国目前的新生儿强制筛查项目不包括脊髓性肌萎缩症,这是儿童中最常见的致命遗传疾病。我们评估了公众对脊髓性肌萎缩症新生儿筛查的偏好,以及测试偏好如何因直接治疗影响而有所不同。

方法

我们对美国成年人(n = 982)进行了一项在线支付意愿调查。受访者被要求想象自己是新生儿的父母。在脊髓性肌萎缩症筛查测试后,每位受访者都面临两种假设情景:当前的护理标准(无可用治疗方法)和三种随机分配情景之一(有可用新治疗方法可改善功能、生存或两者)。我们使用投标博弈来确定支付脊髓性肌萎缩症测试的意愿,并进行两部分模型来估计支付意愿的中位数和平均值。

结果

大多数受访者(79%至87%)更愿意为新生儿进行脊髓性肌萎缩症筛查。即使没有可用治疗方法,人们也表示愿意为脊髓性肌萎缩症筛查付费(中位数:142美元;平均值:253美元)。支付意愿随着治疗方法的可用性(中位数:161美元至182美元;平均值:270美元至297美元)和受访者收入的增加而增加。大多数受访者认为测试准确性、治疗可用性和治疗效果是决定支付意愿的非常重要或重要因素。

结论

即使没有直接治疗,大多数人也更愿意并愿意为新生儿进行脊髓性肌萎缩症检测付费。如果有治疗方法可改善新生儿的功能和生存,人们会认为脊髓性肌萎缩症检测更有价值。尽管对测试信息有偏好,但将脊髓性肌萎缩症纳入新生儿筛查项目仍存在争议。需要进一步研究以确定早期检测如何影响患者的长期预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验